The J8 peptide from the conserved region of the M protein protects against group A streptococcus infections. In this study, we demonstrate that vaccination with a J8-containing formulation induces IgG that recognizes and binds group C and G streptococci. Moreover, this formulation has the potential to provide protection against infections caused by these organisms.
between 45,000 and 80,000 Da (Fig. 1 ). This pattern of binding is similar to that previously observed using monoclonal antibodies generated against the M protein of M6 GAS (21) . The M protein of GAS is known to vary significantly in size, as variations from 41,000 to 80,000 Da in molecular mass have been determined for M proteins extracted from 20 different group A streptococcal serotypes (13) . While the M protein of GAS usually contains between 1 and 3 C-repeat regions, the M protein of GCS and GGS can have up to 5 C-repeat regions contributing to the size variation in the M proteins from different bacterial strains.
We have previously demonstrated that immunization with the J8 peptide conjugated to diphtheria toxoid (DT) protects inbred and outbred mice from virulent challenge with GAS (3). As the J8 sequence and epitope have been detected in both GGS and GCS strains, our next question was whether J8-DT would be protective against GGS and GCS as well. The synthetic J8 peptide was produced as described elsewhere (19) and was conjugated via a C-terminal cysteine residue to DT (CSL, Australia) using 6=-maleimido-caproyl n-hydroxy succinimide (MCS) (7) . The sequence for the J8 peptide is QAEDKVKQSR EAKKQVEKALKQLEDKVQ.
All mouse experiments were approved by the QIMR Animal Ethics Committee, in compliance with the National Health and Medical Research Council of Australia (NHMRC). Thirty micrograms of J8-DT or DT alone, emulsified 1:1 in complete Freund's adjuvant (CFA; Difco Laboratories), was administered subcutaneously to BALB/c mice (Animal Resources Centre, Western Australia). A preparation of total surface proteins from the respective bacteria was used as a positive control, whereas a negative-control group received sterile-filtered phosphate-buffered saline (PBS). Mice were given 2 subsequent booster injections at days 21 and 28 after primary immunization. Blood samples were obtained on days 20, 27, and 35 after primary immunization. An enzymelinked immunosorbent assay (ELISA) was used to measure immunogen-specific murine serum IgG titers. All groups responded to the immunization, and immunogen-specific titers were all above 100,000 (Fig. 2) .
A direct bactericidal assay was performed as previously described (3, 4, 24) . Pooled immune sera from cohorts of mice immunized with MD605 surface protein or J8-DT were capable of the opsonization of the MD605 GCS, with 78% and 39% reductions in CFU, respectively (P values of Ͻ0.05 and Ͻ0.05, respectively, in a nonparametric t test compared to the PBS control group). Similarly, pooled immune sera from cohorts of mice immunized with NS3396 surface protein or J8-DT were capable of the in vitro opsonization of GGS strain NS3396, with 62% (P Ͻ 0.05) and 41% (P Ͻ 0.05) reductions in CFU, respectively. In contrast, pooled sera from cohorts of mice immunized with DT (7%) or PBS (0%) did not significantly kill the NS3396 strain.
Immunized and control mice were challenged with MD605 GCS or NS3396 GGS intraperitoneally 10 days after the final immunization. At time points 8, 24, 32, 48, and 72 h after challenge, spleens from three mice per group were collected and homogenized and aliquots of 50 l were plated out, and on the following day, the numbers of CFU were determined. In the experiment in which the mice were challenged with MD605, a significant difference in clearance in the groups immunized with J8-DT or total surface proteins compared to the group immunized with PBS was detected after 24 h (Fig. 3a) . After 32 h, the bacterial load was completely cleared in the total surface proteins group (not shown) and only a few counts were left in the J8-DT group. In parallel, in the experiment with NS3396, mice immunized with J8-DT cleared the bacteria efficiently (Fig. 3b) . A decrease of the bacterial load in spleens was detected after 24 h, and the counts were lower at all time points than those in all the other groups. No difference was seen between the naive mice and the mice immunized with PBS-CFA (not shown). We have previously observed similar partial protection induced by administration of DT formulated with adjuvant in our GAS studies. In summary, immunization with J8-DT induces an efficacious immune response in vivo against both GCS and GGS, as MD605 and NS3396 were cleared more quickly. Severe streptococcal infections and sequelae are usually due to GAS; however, recent studies suggest that GCS and GGS might also cause acute rheumatic fever (ARF). In a study of an Aboriginal population, cross-reactivity of antibodies to GCS and GGS with human cardiac myosin was demonstrated, suggesting a correlation between GCS and GGS and acute rheumatic fever (16) . Another hypothesis of ARF is that formation of a complex of human basement membrane collagen IV and GAS acts as an autoantigen with rheumatogenic potential (10) . Recently, it has been suggested that GCS and GGS may have a similar ability to cause ARF through collagen autoimmunity (9) .
Even though GCS and GGS are increasingly recognized as pathogens causing a variety of infections similar to those caused by GAS, this is the first vaccine study for GCS and GGS. The studies presented above indicate that a J8-based vaccine to prevent acute rheumatic fever may cover not only GAS infections but also GCS and GGS infections.
